Monday, October 5, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 3, 2026

Global and China Intelligent Vehicle EEA and Technology Supply Chain Construction Strategy Research Report 2025 with EEA Upgrade and Evolution Trends of 17 Chinese OEMs and 7 International OEMs

View original at globenewswire.com
Global and China Intelligent Vehicle EEA and Technology Supply Chain Construction Strategy Research Report 2025 with EEA Upgrade and Evolution Trends of 17 Chinese OEMs and 7 International OEMs Dublin, Feb…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • 802,000 passenger cars with domain fusion architectures were sold in 2025H1, accounting for 7.6% market share

    80% confidence
  • 299,000 passenger cars with central + zonal architectures were sold in 2025H1 with a share of 2.8%

    80% confidence
  • The penetration rate of central + zonal architectures will reach 17.5% by 2030

    80% confidence
  • The penetration rate of quasi-central + zonal architectures will reach 25.2% by 2030

    80% confidence
  • Sentry Mode reduces power consumption by 40%, leading to an additional 16km of range for the vehicle

    80% confidence
  • The four-in-one domain controller enables 15-minute OTA updates

    80% confidence
  • The four-in-one domain controller achieves 57% reduction in size and 75% fewer parts compared to traditional distributed architecture

    80% confidence
  • 640,000 passenger cars with quasi-central + zonal architectures were sold in 2025H1 with a share of 6.1%

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com
Global and China Intelligent Vehicle EEA and Technology Supply Chain Construction Strategy Research Report 2025 with EEA Upgrade and Evolution Trends of 17 Chinese OEMs and 7 International OEMs — Source | Via News | Via News